66 results
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
5:16pm
or governmental entities; the ability to retain and hire key personnel; potential adverse reactions or changes to business relationships resulting from
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
5:17pm
partners or governmental entities; the ability to retain and hire key personnel; potential adverse reactions or changes to business relationships
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
5:14pm
with Surface’s or the Company’s employees, business or collaboration partners or governmental entities; the ability to retain and hire key personnel; potential
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
5:14pm
, business or collaboration partners or governmental entities; the ability to retain and hire key personnel; potential adverse reactions or changes
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
employees, business or collaboration partners or governmental entities; the ability to retain and hire key personnel; potential adverse reactions
8-K
vhvzsf3 wgh6f6opu
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
DRS/A
EX-10
4sbb6v7u eny0e
24 Sep 14
Draft registration statement (amended)
12:00am
425
ihunfhs4pd5hfz1
16 Jun 23
Business combination disclosure
5:12pm
8-K
EX-2.1
kar4ax 79ztrywrpm
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
425
ptp8f6maa48 d8
16 Jun 23
Business combination disclosure
5:11pm